Hagop Kantarjian/ mdanderson.org
Feb 8, 2024, 05:16
Hagop Kantarjian: A new standard of care in newly diagnosed older FLT3-mutated AML
Hagop Kantarjian, Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, shared on X:
“Aza + ven + gilteritinib highly effective in newly diagnosed older FLT3-mutated AML: CR/CRi 96% and 18-month OS 72%. A new standard of care in this population.”
Visit the article website.
Source: Hagop Kantarjian/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 21, 2025, 13:07
Feb 21, 2025, 13:06
Feb 21, 2025, 13:03
Feb 21, 2025, 13:00
Feb 21, 2025, 12:53
Feb 21, 2025, 12:41
Feb 21, 2025, 12:39